Russia will seek authorisation from SA’s medicines regulator for its single-shot Sputnik Light coronavirus vaccine after a study showed it is 70% effective at preventing transmission of the Delta variant three months after inoculation.

Sputnik Light is the first component of the two-shot Sputnik V vaccine, developed by the Gamaleya National Research Centre of Epidemiology and Microbiology with backing from the Russian Direct Investment Fund (RDIF). It has been authorised as a stand-alone vaccine in more than 15 countries, while Sputnik V has been approved in 70 countries...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now